CYP4B1 and lung adenocarcinoma: Additionally, CYP4B1 was positively associated with immune checkpoints such as PD-1 and PD-L1; these findings suggest that CYP4B1 could serve as a favorable prognostic biomarker and holds predictive value in the context of immunotherapy for lung adenocarcinoma [82].